共查询到18条相似文献,搜索用时 140 毫秒
1.
目的:探索醛脱氢酶1A1(aldehyde dehydrogenase 1A1,ALDH1A1)在肺腺癌细胞(lung adenocarcinoma cell,LAC)化疗耐药中的作用及机制,为肺癌临床治疗和新型药物的研发提供实验依据。方法:采用慢病毒载体构建ALDH1A1高表达肺腺癌细胞模型,并通过流式细胞术和western blot技术对该细胞模型进行验证。通过CCK8法检测ALDH1A1高表达肺腺癌细胞对肺癌治疗药物顺铂(cisplatin,DDP)、紫杉醇(paclitaxcel)、厄洛替尼(erlotinib)和吉非替尼(gefitinib)的耐药性。通过检测肿瘤干细胞(cancer stem cell,CSC)分子标志物、上皮-间质转化(Epithelial-Mesenchymal Transition,EMT)分子标志物及细胞迁移能力探讨ALDH1A1高表达对肺腺癌细胞的干性和EMT特征的影响。双硫仑(disulfiram,DSF)是ALDH的抑制剂,我们通过CCK8法和transwell细胞迁移实验探究DSF对肺腺癌细胞体外生长和迁移能力的影响,体内实验探究DSF和厄洛替尼联合用药对HCC827-ALDH1A1细胞皮下异种移植瘤生长的影响。结果:ALDH1A1高表达诱导肺腺癌细胞对厄洛替尼、吉非替尼、紫杉醇和顺铂产生不同程度的耐药,干细胞标志物CD44、CD133蛋白表达上调,EMT间充质标志物vimentin蛋白表达上调,transwell实验结果显示ALDH1A1高表达肺腺癌细胞的迁移能力增强,使用ALDH靶向抑制剂DSF能选择性抑制ALDH1A1高表达肺腺癌细胞所增高的迁移能力并克服HCC827-ALDH1A1细胞皮下异种移植瘤的生长,延缓体内耐药。结论:ALDH1A1能诱导肺腺癌细胞对多种抗肺癌药物产生耐药并发生干细胞样转化,靶向抑制ALDH酶活性可克服由ALDH1A1高表达所产生的耐药,为肺癌的临床治疗提供新的思路。 相似文献
2.
本文研究除痰解毒方(Chutan Jiedu Decoction,CJD)联合吉非替尼对肺腺癌H1975荷瘤小鼠移植瘤twist、fibronectin表达的影响,从上皮间质转化(Epithelial-mesenchymal transition,EMT)角度探讨其抗肿瘤作用机制。建立人肺腺癌H1975耐药细胞荷瘤裸鼠模型,随机分为模型组,吉非替尼组,除痰解毒方低、中、高剂量组,除痰解毒方中剂量联合吉非替尼组,每组10只,各组予以相应的药物灌胃2周。检测瘤体积和瘤质量,计算抑瘤率,采用免疫组织化学法、Western blot法、荧光定量PCR法检测各组肿瘤组织twist、fibronectin蛋白及基因的表达。结果显示,联合用药组抑瘤率为61.92%,明显高于模型组、吉非替尼组,除痰解毒方低、中、高剂量组(P0.01)。免疫组织化学法、Western blot法及荧光定量PCR法结果均显示除痰解毒方中剂量、高剂量及联合用药组均能下调twist和fibronectin的表达,且联合用药组下调作用高于单独用药组(P0.01)。研究结果表明除痰解毒方联合吉非替尼对肺腺癌H1975荷瘤小鼠移植瘤生长及twist、fibronectin表达的抑制作用优于除痰解毒方单药及吉非替尼组,其协同增效作用可能与逆转EMT增强吉非替尼的敏感性有关。 相似文献
3.
摘要 目的:探讨靶向抗凋亡蛋白Bcl-2克服非小细胞肺癌EGFR-TKIs耐药的作用及重定位Bcl-2靶向抑制剂用于克服耐药的可行性。方法:通过药物浓度梯度递增法构建非小细胞肺癌多代EGFR-TKIs耐药株,根据亲本细胞和多代EGFR-TKIs耐药的非小细胞肺癌细胞的RNA-seq数据筛选出潜在耐药相关基因Bcl-2,通过Western blot 检测其在耐药细胞中的蛋白水平。为了探讨Bcl-2诱导耐药的作用,采用siRNA干扰和使用Bcl-2的抑制剂ABT199抑制Bcl-2,通过CCK8法、IncuCyte实时监测和Western blot等方法检测其对亲本和耐药细胞的细胞活力、药物敏感性、增殖和凋亡的影响。随后使用奥希替尼分别处理亲本及耐药细胞,通过Western Blot检测NRF2受到药物作用后及在耐药细胞中的蛋白水平,并以临床公共数据库分析辅助验证。使用siRNA干扰或NRF2抑制剂ML385敲低或抑制NRF2功能,借助Western Blot和CCK8法检测其对Bcl-2表达水平及对EGFR-TKI敏感性的影响;通过加入NRF2的激动剂Ki696探究其对Bcl-2的诱导作用、对EGFR-TKI敏感性的影响及取消靶向Bcl-2逆转耐药的作用。结果:Bcl-2在EGFR-TKIs耐药细胞中上调;敲低或抑制Bcl-2后,可选择性抑制耐药细胞的生长和活力,并诱导凋亡,且能逆转包括第三代药物奥希替尼在内的多代EGFR-TKIs耐药;EGFR-TKI可在敏感细胞中诱导NRF2的上调,且耐药细胞中上调的Bcl-2受NRF2调控。结论:EGFR-TKIs耐药细胞通过上调抗凋亡分子Bcl-2获得耐药,该分子的上调受NRF2的调控,靶向Bcl-2则可以逆转耐药。 相似文献
4.
目的:研究丝氨酸生物合成途径(SSP)在肺腺癌使用表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)治疗后引起的适应性耐药中发挥的作用,探究早期适应性耐药机制以寻找抗耐药靶标。方法:使用EGFR-TKIs药物短时刺激肺腺癌细胞系后,利用Western blotting和qRT-PCR技术检测丝氨酸生物合成途径中关键酶的蛋白及m RNA水平变化,同时利用LC-MS检测细胞内丝氨酸生物合成途径产物及相关代谢产物变化情况。通过CCK8法检测敲低关键酶对细胞增殖的影响。体内实验进行肺腺癌细胞裸鼠皮下移植瘤注射,采用剂量爬坡法构建体内适应性耐药模型,检测肿瘤组织中关键酶表达情况。结果:1.细胞内丝氨酸生物合成途径关键酶PHGDH、PSAT1、PSPH的蛋白表达水平在不同药物作用时间和浓度下有不同程度上调,且m RNA水平也上调了20-50%左右(P0.05);2.HCC827细胞中SSP及下游代谢通路产物如P-Serine、Serine、Glycine、AMP等均有显著性上调(P0.01);3.敲低关键酶PSAT1及PSPH后可抑制细肺腺癌细胞HCCC827及PC9的增殖,与对照组相比最高抑制率可达60%左右(P0.01);4.体内诱导PC9细胞适应性耐erlotinib后,肿瘤组织中的PHGDH及PSAT1表达均有明显上调。结论:丝氨酸生物合成途径介导了肺腺癌EGFR-TKIs靶向治疗的适应性耐药,其关键酶有望作为抗耐药靶标进行联合治疗,从而提高EGFR-TKIs靶向药物的早期疗效并最终克服耐药性的产生。 相似文献
5.
目的:探究Chk1反义寡核苷酸(CHK1-ASODN)单独或联合顺铂(DDP)对卵巢癌细胞系SKOV-3侵袭转移能力的影响,并阐明其可能的分子机制。方法:体外培养人卵巢癌细胞系SKOV-3,CHK1-ASODN单独或联合DDP处理48 h后,划痕实验检测细胞迁移能力;Transwell实验检测细胞侵袭能力;显微镜下观察细胞上皮或间质表型特征;Western blot及实时定量PCR技术分别检测上皮间质转化(EMT)特异性标志物(E-cadherin、N-cadherin)以及EMT关键调控分子ZEB1的蛋白及m RNA的表达水平。结果:与对照组相比较,CHK1-ASODN单独或联合DDP均能显著抑制SKOV-3细胞的迁移及侵袭(P0.05);细胞表现为间质化表型;E-cadherin的表达显著升高(P0.05),而N-cadherin的表达则显著降低(P0.05);ZEB1的表达显著降低(P0.05)。结论:CHK1-ASODN单独或联合DDP下调ZEB1的表达进而逆转EMT可能是其抑制卵巢癌侵袭转移的重要机制之一。 相似文献
6.
该研究探讨了薯蓣皂苷(Dioscin)对三阴性乳腺癌MDA-MB-231、BT549细胞体外侵袭及上皮–间质转化(epithelial to mensenchymal transition,EMT)的影响及其作用机制。以正常人乳腺上皮MCF-10A细胞为对照,通过MTS法、克隆形成实验检测细胞增殖能力;Transwell实验检测细胞侵袭、迁移能力;Western blot法检测p38MAPK、p-p38MAPK、FOXO3a及上皮–间质转化(epithelial to mensenchymal transition,EMT)相关标志物的表达。结果显示,Dioscin能明显抑制MDA-MB-231、BT549细胞的增殖,且具有浓度依赖性,对MCF-10A细胞抑制作用较弱;Dioscin处理后肿瘤细胞的侵袭、迁移能力明显降低,Dioscin可显著下调细胞间质样标志物波形蛋白(vimentin)、N-钙黏蛋白(N-cadherin)并促进上皮样标志物E-钙黏蛋白(E-cadherin)的表达,EMT关键转录因子Snail的表达也受到抑制。进一步研究发现,Dioscin能够上调p38MAPK磷酸化水平并促进转录因子FOXO3a的表达,而干扰FOXO3a能够逆转Dioscin对细胞EMT及侵袭的抑制作用。以上研究表明,Dioscin能够抑制三阴性乳腺癌细胞EMT及体外侵袭、迁移能力,其机制可能与Dioscin调控p38MAPK/FOXO3a信号有关。 相似文献
7.
目的:探讨瞬时受体电位离子通道3(Transient receptor potential melastatin 3,TRPM3)对卵巢癌侵袭转移和上皮细胞间质转化(Epithelial mesenchymal transition,EMT)的影响及其分子作用机制。方法:采用小干扰RNA沉默上皮性卵巢癌细胞株中HEY及SKOV3中TRPM3的表达,通过Transwell实验和划痕实验检测上皮性卵巢癌细胞的侵袭和迁移能力的变化,Western Blot检测EMT相关蛋白、Wnt/β-catenin通路相关蛋白的表达情况。结果:与对照组细胞相比,干扰组的上皮性卵巢癌细胞迁移和侵袭能力均明显减弱,EMT相关蛋白的上皮细胞标志分子E-cadherin的表达上调,间质细胞标志分子N-cadherin和EMT相关转录调控因子Snail的表达下调,Wnt/β-catenin通路相关蛋白CyclinD1、β-catenin的表达下调。结论:TRPM3可能通过激活Wnt/β-catenin通路促进卵巢癌细胞的上皮间质转化过程,进而增强其侵袭转移的能力。 相似文献
8.
《中国生物化学与分子生物学报》2015,(7)
上皮间质转化(epithelial-mesenchymal transition,EMT)与肿瘤侵袭转移密切相关.虽然肝细胞生长因子(hepatocyte growth factor,HGF)已被证实为肿瘤EMT的主要诱导剂,但是HGF诱导肿瘤EMT发生的分子机制尚不完全清楚.本研究旨在探讨Snail在HGF诱导肝癌细胞上皮间质转化中的作用.用HGF处理肝癌Hep G2和Hep3B细胞,显微镜观察细胞形态变化,划痕试验及Transwell试验检测细胞迁移能力,Western印迹检测Met,AKT的磷酸化及蛋白质表达的变化,Western印迹与real-time RT-PCR检测上皮细胞表面标志E-Cadherin和间质细胞表面标志NCadherin、Fibronectin的表达变化,以及EMT相关转录因子的表达变化.经HGF处理的Hep G2、Hep3B细胞,Met和AKT的磷酸化水平显著增强;相差倒置显微镜下观察细胞形态向间质型细胞形态转化;细胞划痕和Transwell试验检测细胞的迁移能力较对照组显著增强;Real-time RT-PCR和Western印迹实验显示HGF的诱导能上调间质标记蛋白的表达及下调上皮型标志蛋白的表达.进一步发现,HGF能上调转录因子Snail的表达,干扰Snail能逆转HGF对Hep G2和Hep 3B细胞EMT发生的诱导作用.由此可见,HGF可能通过诱导Snail的表达促进肝癌细胞EMT的发生.这为阐明肝癌细胞侵袭转移机制,以及肝癌的防治提供新线索. 相似文献
9.
目的:探讨FEN-1和AXL在上皮性卵巢癌组织表达情况及其与卵巢癌化疗耐药的关系。方法:采用免疫组化法检测卵巢癌/正常卵巢组织中FEN-1及AXL表达,分析蛋白表达与卵巢癌化疗疗效相关性。结果:卵巢癌组织中FEN-1及AXL阳性率分别为58.20%及72.13%,均显著高于正常卵巢组织(10%)(P0.05)。相对早期患者,FEN-1高表达于晚期卵巢癌组织(37.50%63.27%)(P0.05),与分化程度及化疗敏感性关系不大(P0.05)。AXL高表达于晚期卵巢癌(77.55%50%)及低分化组织中(79.71%62.26%)(P0.05)。癌组织AXL阳性者化疗有效率(51.14%)明显低于阴性者(85.29%)(P0.05);化疗耐药组AXL阳性率(89.58%)明显高于敏感组(60.81%)(P0.05)。结论:FEN-1及AXL均与卵巢癌发生发展相关,AXL的表达可作为预测卵巢癌化疗耐药的指标。 相似文献
10.
先前研究表明,miR-186-5p在人类许多恶性肿瘤中扮演抑癌基因的作用,但其在肺腺癌上皮-间质转化(epithelial-mesenchymal transition,EMT)中的作用并不明确。本研究旨在证明,miR-186-5p可通过靶向调控PTTG1抑制肺腺癌细胞的上皮-间质转化。我们首先分析了miR-186-5p在人肺癌细胞中的表达。荧光定量PCR(QRT-PCR)结果显示,与人正常肺上皮细胞BEAS-2B相比,肺腺癌细胞SPC-A1、A549中的miR-186-5p表达量明显降低。为研究miR-186-5p在肺腺癌细胞中的功能,利用GV369-miR-186-5p表达载体,实现了在A549细胞中的过表达。基因转染结合Transwell侵袭结果显示,与对照质粒转染的A549细胞相比,过表达miR-186-5p的A549细胞的体外侵袭能力明显下降。Western印迹检测细胞中EMT相关标志物揭示,GV369-miR-186-5p转染的A549细胞中的上皮-钙黏着蛋白(E-cadherin)表达明显上调,而神经-钙黏着蛋白(N-cadherin)和波形蛋白(vimentin)表达明显下调。同时,GV369-miR-186-5p转染引起其靶基因--垂体肿瘤转化基因1(pituitary tumor-transforming gene 1,PTTG1)编码蛋白在A549细胞中明显降低。重要的是,过表达miR-186-5p与敲减PTTG1均可导致上皮-钙黏着蛋白表达上调,而神经-钙黏着蛋白和波形蛋白下调|而miR-186-5p和PTTG1表达载体共转染后,3种EMT相关标志物在A549的表达与对照细胞的表达无明显差异,提示过表达PTTG1可抵消miR-186-5p对EMT相关标志物表达的影响。综上所述,miR-186-5p可通过靶向调控PTTG1抑制EMT的发生,进而抑制肺腺癌细胞的侵袭转移。 相似文献
11.
Hiroshi Mizuuchi Kenichi Suda Katsuaki Sato Shuta Tomida Yoshihiko Fujita Yoshihisa Kobayashi Yoshihiko Maehara Yoshitaka Sekido Kazuto Nishio Tetsuya Mitsudomi 《PloS one》2015,10(4)
Various alterations underlying acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have been described. Although treatment strategies specific for these mechanisms are under development, cytotoxic agents are currently employed to treat many patients following failure of EGFR-TKIs. However, the effect of TKI resistance on sensitivity to these cytotoxic agents is mostly unclear. This study investigated the sensitivity of erlotinib-resistant tumor cells to five cytotoxic agents using an in vitro EGFR-TKI-resistant model. Four erlotinib-sensitive lung adenocarcinoma cell lines and their resistant derivatives were tested. Of the resistant cell lines, all but one showed a similar sensitivity to the tested drugs as their parental cells. HCC4006ER cells with epithelial mesenchymal transition features acquired resistance to the three microtubule-targeting agents, docetaxel, paclitaxel and vinorelbine, but not to cisplatin and gemcitabine. Gene expression array and immunoblotting demonstrated that ATP-binding cassette subfamily B, member 1 (ABCB1) was up-regulated in HCC4006ER cells. ABCB1 knockdown by siRNA partially restored sensitivity to the anti-microtubule agents but not to erlotinib. Moreover, the histone deacetylase inhibitor entinostat sensitized HCC4006ER cells to anti-microtubule agents through ABCB1 suppression. Our study indicates that sensitivity of tumor cells to cytotoxic agents in general does not change before and after failure of EGFR-TKIs. However, we describe that two different molecular alterations confer acquired resistance to EGFR-TKIs and cytotoxic agents, respectively. This phenomenon should be kept in mind in selection of subsequent therapy after failure of EGFR-TKIs. 相似文献
12.
Background
The epidermal growth-factor receptor tyrosine kinase inhibitors have been effective in non-small cell lung cancer patients. However, acquired resistance eventually develops in most patients despite an initial positive response. Emerging evidence suggests that there is a molecular connection between acquired resistance and the epithelial–mesenchymal transition (EMT). N-cadherin is involved in the EMT and in the metastasis of cancer cells. Here, we analyzed N-cadherin expression and function in erlotinib-resistant lung cancer cell lines.Methods
H1650 cell lines were used to establish the subline resistant to erlotinib(H1650ER). Then, induction of the EMT was analyzed using immunostaining and western blots in H1650ER cells. N-cadherin expression in the resistant cells was examined using FACS and western blot. In addition, an invasion assay was performed to characterize the resistant cells. The effects of N-cadherin on cell proliferation and invasion were analyzed. The association of N-cadherin expression with the EMT phenotype was investigated using immunohistochemical analysis of 13 archived, lung adenocarcinoma tissues, before and after treatment with erlotinib.Results
In H1650ER cells, N-cadherin expression was upregulated, paralleled by the reduced expression of E-cadherin. The marked histological change and the development of a spindle-like morphology suggest that H1650ER cells underwent an EMT, accompanied by a decrease in E-cadherin and an increase in vimentin. A change in the EMT status between pre-and post-treatment was observed in 11 out of 13 cases (79%). In biopsies of resistant cancers, N-cadherin expression was increased in 10 out of 13 cases. Induction of the EMT was consistent with aggressive characteristics. Inhibition of N-cadherin expression by siRNA was tested to reduce proliferation and invasion of H1650ER cells in vitro.Conclusions
Our data provide evidence that induction of the EMT contributes to the acquired resistance to EGFR-TKIs in lung cancer. It suggests that N-cadherin is a potential molecular target in the treatment of NSCLC. 相似文献13.
Takeshi Yoshida Lanxi Song Yun Bai Fumi Kinose Jiannong Li Kim C. Ohaegbulam Teresita Mu?oz-Antonia Xiaotao Qu Steven Eschrich Hidetaka Uramoto Fumihiro Tanaka Patrick Nasarre Robert M. Gemmill Jo?lle Roche Harry A. Drabkin Eric B. Haura 《PloS one》2016,11(1)
Epithelial-mesenchymal transition (EMT) is one mechanism of acquired resistance to inhibitors of the epidermal growth factor receptor-tyrosine kinases (EGFR-TKIs) in non-small cell lung cancer (NSCLC). The precise mechanisms of EMT-related acquired resistance to EGFR-TKIs in NSCLC remain unclear. We generated erlotinib-resistant HCC4006 cells (HCC4006ER) by chronic exposure of EGFR-mutant HCC4006 cells to increasing concentrations of erlotinib. HCC4006ER cells acquired an EMT phenotype and activation of the TGF-β/SMAD pathway, while lacking both T790M secondary EGFR mutation and MET gene amplification. We employed gene expression microarrays in HCC4006 and HCC4006ER cells to better understand the mechanism of acquired EGFR-TKI resistance with EMT. At the mRNA level, ZEB1 (TCF8), a known regulator of EMT, was >20-fold higher in HCC4006ER cells than in HCC4006 cells, and increased ZEB1 protein level was also detected. Furthermore, numerous ZEB1 responsive genes, such as CDH1 (E-cadherin), ST14, and vimentin, were coordinately regulated along with increased ZEB1 in HCC4006ER cells. We also identified ZEB1 overexpression and an EMT phenotype in several NSCLC cells and human NSCLC samples with acquired EGFR-TKI resistance. Short-interfering RNA against ZEB1 reversed the EMT phenotype and, importantly, restored erlotinib sensitivity in HCC4006ER cells. The level of micro-RNA-200c, which can negatively regulate ZEB1, was significantly reduced in HCC4006ER cells. Our results suggest that increased ZEB1 can drive EMT-related acquired resistance to EGFR-TKIs in NSCLC. Attempts should be made to explore targeting ZEB1 to resensitize TKI-resistant tumors. 相似文献
14.
《Bioorganic & medicinal chemistry letters》2014,24(18):4553-4556
The clinical application of gallium compounds as anticancer agents is hampered by development of resistance. As a potential strategy to overcome the limitation, eight series of compounds were identified through virtual screening of AXL kinase homology model. Anti-proliferative studies were carried using gallium-sensitive (S) and gallium-resistant (R) human lung adenocarcinoma (A549) cells. Compounds 5476423 and 7919469 were identified as leads. The IC50 values from treating R-cells showed compounds 5476423 and 7919469 had 80 fold and 13 fold increased potency, respectively, compared to gallium acetylacetonate (GaAcAc). The efficacy of GaAcAc against R-cells was increased 2 fold and 1.2 fold when combined with compounds 5476423 and 7919469, respectively. Compared with S-cells, R-cells showed elevated expression of AXL protein, which was significantly suppressed through treatments with the lead compounds. It is anticipated that the lead compounds could be applied in virtual screening programs to identify novel scaffolds for new therapeutic agents as well as combinatorial therapy agents in gallium resistant lung cancer. 相似文献
15.
Qian Han Peng Cheng Hongjie Yang Hengpo Liang Fengchun Lin 《Journal of cellular biochemistry》2020,121(8-9):3901-3912
Epithelial-mesenchymal transformation (EMT) is associated with drug resistance in human lung adenocarcinoma cells, but its specific mechanism has not been clarified. In this study, we investigated the effect of miRNA-146b on EMT in cisplatin (DDP) resistant human lung adenocarcinoma cells and the corresponding mechanism. Cisplatin resistant (CR) human lung adenocarcinoma cells (A549/DDP and H1299/DDP) were established, and the EMT characteristics and invasion and metastasis ability of CR cells were determined by tumor cell-related biological behavior experiments. The role of miR-146b in EMT of CR cells was determined by in vitro functional test. The targeted binding of miR-146b to protein tyrosine phosphatase 1B (PTP1B) was verified by biological information and double luciferin gene reporting experiments. The effect of miR-146b on tumor growth and EMT phenotype in vivo was investigated by establishing the xenotransplantation mouse model. Compared with the control group, H1299/DDP and A549/DDP cells showed the enhanced EMT phenotypes, invasion and migration ability. Besides, miR-146b was lowly expressed in H1299/DDP and A549/DDP cells. More importantly, overexpressed miR-146b could specifically bind to PTP1B, thus inhibiting the EMT process and ultimately reducing CR in H1299/DDP and A549/DDP cells. Finally, overexpressed miR-146b observably inhibited tumor growth in xenograft model mice and inhibited the EMT phenotype of A549/DDP cells in vivo by regulating the expressions of EMT-related proteins. Overexpressed miR-146b could reverse the EMT phenotype of CR lung adenocarcinoma cells by targeting PTP1B, providing new therapeutic directions for CR of lung adenocarcinoma cells. 相似文献
16.
摘要 目的:通过实验探究miR-142靶向高迁移率族蛋白1(high-mobility group box 1 protein,HMGB1)对宫颈癌(cervical cancer,CC)细胞生物学行为的影响及其潜在的作用机制。方法:采用实时荧光定量PCR(RT-PCR)和蛋白质免疫印迹法(Western Blot)检测CC组织和正常组织中miR-142和HMGB1 mRNA及蛋白表达水平,采用荧光素酶报告实验分析miR-142与HMGB1的靶向关系,CCK-8法检测CC细胞生存能力,克隆形成实验检测CC细胞增殖能力,划痕修复实验检测CC细胞迁移能力,基质胶侵袭实验检测CC细胞侵袭能力。结果:CC组miR-142 mRNA和蛋白表达水平显著低于正常组(P<0.05),HMGB1 mRNA和蛋白表达水平显著高于正常组(P<0.05),且CC癌组织中miR-142和HMGB1 mRNA和蛋白表达水平均呈显著负相关(r=-0.399,P=0.002;r=-0.429,P=0.001);miR-142与HMGB1存在靶向关系;CCK-8法实验、克隆形成实验、划痕修复实验和基质胶侵袭实验结果显示,miR-142 mimic组细胞生存、增殖、迁移和侵袭能力显著低于miR-NC组(P<0.05),miR-142 inhibitor组细胞生存、增殖、迁移和侵袭能力显著高于miR-NC组;Western Blot实验结果显示,HMGB1过表达时miR-142 mimic+plasmid组HMGB1蛋白表达水平显著高于miR-142 mimic+control plasmid组(P<0.05),显著低于miR-NC+plasmid组(P<0.05);CCK-8法实验、克隆形成实验、划痕修复实验和基质胶侵袭实验结果显示,HMGB1过表达时miR-142 mimic+plasmid组细胞生存、增殖、迁移和侵袭能力显著高于miR-142 mimic+control plasmid组(P<0.05),显著低于miR-NC+plasmid组(P<0.05)。结论:miR-142可通过靶向负调控HMGB1表达,进而抑制CC细胞生存、增殖、迁移和侵袭。 相似文献
17.
18.
Lentivirus‐mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro
下载免费PDF全文
![点击此处可从《Biotechnology progress》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Ya‐Qing Li Yuan‐Shun Liu Xi‐Wang Ying Hong‐Bin Zhou Zhehua Wang Sheng‐Chang Wu Jian‐Ping Yan Yu‐Ting Jing Yang Yang 《Biotechnology progress》2018,34(1):196-205